News
Future trends in Bladder Cancer treatment
BCa19, held in Turin on 17-18 May, is set to bring together a lot of opinion leaders in bladder cancer who will be giving very practical talks and case-based discussions that will cover many aspects of BCa treatment relevant...
Prof. Peter Black: “An exciting time in the field of BCa”
While progress in bladder cancer treatment has lagged behind other cancers in previous decades, the EAU’s BCa19 meeting comes at a time when experts are seeing the emergence of a lot of new developments, according to Prof. Peter Black...
“A thorough and updated overview of BCa for any clinician involved in multidisciplinary care”
After a successful inaugural meeting last year in Munich, the EAU is continuing to offer a two-day educational update on the topic of bladder cancer. The meeting is specifically designed to give participants a practical, high-quality and comprehensive update...
BCa18: Benefits of ERAS following radical cystectomy
Radical cystectomy is the standard for muscle-invasive bladder cancer and with mostly elderly men as patients, doctors are seeking ways to improved recovery regimes following radical surgeries. “64% of patients have one or more complications, 13% have a major...
BCa18: Gains and prospects in BCa classification and treatment
There are increment developments in genomics research on bladder cancer (BCa) molecular classification, but drug development and their prospective benefits still remain unclear due to the complex types of aggressive disease and the lack of sufficient patient numbers in...
BCa18: MIBC guidelines need more work but prospects are emerging
There is a lot of work that needs to be done to address gaps in the guidelines for managing muscle-invasive bladder cancer (MIBC), but at the same time, there are new prospects in biological predictors that could transform the...
BCa18: Experts examine gaps in actual practice and guidelines for NMIBC
Refining current guidelines to reflect the evolving treatment strategies in non-muscle invasive bladder cancer (NMIBC) and the need for a more collaborative and responsive multidisciplinary teamwork were among the main topics examined at the first plenary session of the...
Identifying potential road maps in personalising BCa treatment
Bladder cancer, one of the most aggressive recurrent onco-urological malignancies, poses a special challenge to cancer experts due to the lack of response from many patients particularly those who are diagnosed at a late stage. The EAU Update on...
Advances in classifying BCa variants to boost therapeutic options
Recent gains in precisely identifying bladder cancer variants and their respective classification can go a long way in enabling physicians to determine the proper treatment, which leads to better or timely therapies for many bladder cancer patients. Bladder cancer...
Identifying high-risk patients: Key for optimal BCa management
For many physicians bladder cancer management is replete with challenges and pitfalls, and with the recent developments in drug development and molecular classifications, specialists encounter dilemmas that prompt a critical look at both current practices and novel treatment options....